vorozole has been researched along with Hormone-Dependent Neoplasms in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (62.50) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E | 1 |
Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP | 1 |
Buzdar, AU; Roseman, BJ; Singletary, SE | 1 |
Harvey, HA | 1 |
Dowsett, M | 1 |
Goss, PE | 1 |
Harvey, HA; Santen, RJ | 1 |
Bijnens, L; Michiels, B; Molenberghs, G; Thijs, H; Vangeneugden, T | 1 |
7 review(s) available for vorozole and Hormone-Dependent Neoplasms
Article | Year |
---|---|
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Probability; Prognosis; Remission Induction; Risk Assessment; Survival Analysis; Triazoles | 2005 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2006 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 1998 |
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Enzyme Inhibitors; Humans; Neoplasms, Hormone-Dependent; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
1 other study(ies) available for vorozole and Hormone-Dependent Neoplasms
Article | Year |
---|---|
Selection models and pattern-mixture models to analyse longitudinal quality of life data subject to drop-out.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Female; Humans; Longitudinal Studies; Models, Statistical; Neoplasms, Hormone-Dependent; Patient Dropouts; Quality of Life; Triazoles | 2002 |